Clinical efficacy of tolvaptan in acute decompensated heart failure patients with severe aortic stenosis and atrial fibrillation: a sub-analysis from the LOHAS registry.
Tsutomu MurakamiYusuke WatanabeNorihito NakamuraMakoto NatsumedaYohei OhnoGaku NakazawaYuji IkariAkihisa KataokaYosuke NishihataKentaro HayashidaMasanori YamamotoJun TanakaKentaro JujoMasaki IzumoKazuki MizutaniKen KozumaPublished in: Heart and vessels (2024)
Short-term treatment with tolvaptan improved HF in patients hospitalized for severe AS, regardless of the presence of AF or SR. After achieving sufficient diuresis, a slight decrease in blood pressure was observed in the AF group, suggesting an appropriate timeframe for safe and effective use of tolvaptan.
Keyphrases
- ejection fraction
- atrial fibrillation
- heart failure
- aortic stenosis
- acute heart failure
- blood pressure
- left ventricular
- end stage renal disease
- aortic valve replacement
- transcatheter aortic valve replacement
- liver failure
- transcatheter aortic valve implantation
- early onset
- left atrial
- chronic kidney disease
- newly diagnosed
- drug induced
- oral anticoagulants
- polycystic kidney disease
- catheter ablation
- left atrial appendage
- direct oral anticoagulants
- type diabetes
- peritoneal dialysis
- metabolic syndrome
- coronary artery disease
- percutaneous coronary intervention
- cardiac resynchronization therapy
- extracorporeal membrane oxygenation
- blood glucose
- adipose tissue
- respiratory failure
- skeletal muscle
- patient reported